ArticleRheumatology and therapy2026
Pain Reduction Improves Adherence, Quality of Life, and Work Capacity in Rheumatoid Arthritis Patients Receiving Baricitinib: Czech ATTRA Registry Analysis.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionDespite achieving targets of inflammation reduction, many patients with rheumatoid arthritis (RA) report persistent pain and reduced quality of life (QoL). Biologic and targeted RA therapies produce similar improvements in disease activity, but varying improvements in pain. Baricitinib is a Janus kinase inhibitor that has demonstrated greater and more pain relief compared to either methotrexate or adalimumab.
methodsThis study examines 24-month registry data from real-world patients receiving baricitinib in the Czech Republic. The aim was to determine the impact of baseline pain intensity on treatment survival and its correlation with QoL and work capacity.
resultsData from 392 patients (83.2% women) were analysed, with the majority (75.8%) having prior experience with biologic/targeted therapeutics. At baseline, disease activity (mean Disease Activity Score 28 Erythrocyte Sedimentation Rate [DAS28-ESR] of 5.6 [± 1.2]) and pain Visual Analogue Scale (VAS) (61.2 [± 22.5] mm) were high. Mean DAS28-ESR decreased to 3.3 (± 1.1) after 3 months and 2.7 (± 1.0) after 24 months; mean pain VAS decreased to 36.4 (± 23.4) mm and 30.8 (± 22.7) mm. We observed negative correlations between baseline pain VAS and treatment survival, and positive correlations between baseline pain VAS and work/activity impairment (strong in all components [ρ = 0.73-0.78] except absenteeism [absence from work, ρ = 0.20]). Pain VAS was also negatively correlated with QoL at all timepoints (p < 0.001).
conclusionTreatment with baricitinib provided sustained pain reduction and decreased disease activity in patients with RA. Findings highlight the need for pain-focused treatment goals and suggest earlier intervention may enhance persistence and QoL. Work limitations persisted, highlighting the need for flexible employment policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.